# Jörn M. Schattenberg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jorn-m-schattenberg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,180 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 80 |
| i10-index | 267 |
| Last Known Institution | Universitätsklinikum des Saarlandes |
| OpenAlex ID | https://openalex.org/A5090959657 |
| ORCID iD | 0000-0002-4224-4703 |
| Works | 811 |

## Researcher papers

Showing 12 of 20.

- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030](https://scholariq.org/papers/modeling-nafld-disease-burden-in-china-france-germany-italy-japan-spain-united/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [NASH limits anti-tumour surveillance in immunotherapy-treated HCC](https://scholariq.org/papers/nash-limits-anti-tumour-surveillance-in-immunotherapy-treated-hcc/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/association-between-fibrosis-stage-and-outcomes-of-patients-with-nonalcoholic/)
- [Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis](https://scholariq.org/papers/age-as-a-confounding-factor-for-the-accurate-non-invasive-diagnosis-of-advanced/)
- [Advancing the global public health agenda for NAFLD: a consensus statement](https://scholariq.org/papers/advancing-the-global-public-health-agenda-for-nafld-a-consensus-statement/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆](https://scholariq.org/papers/genome-wide-association-study-of-non-alcoholic-fatty-liver-and-steatohepatitis/)
- [Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-non-invasive-tests-for-advanced-fibrosis-in-patients-with/)
- [Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials](https://scholariq.org/papers/selonsertib-for-patients-with-bridging-fibrosis-or-compensated-cirrhosis-due-to/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Diet, Metabolism, and Disease](https://scholariq.org/topics/diet-metabolism-and-disease/)

## Researcher university

- [Universitätsklinikum des Saarlandes](https://scholariq.org/institutions/universitatsklinikum-des-saarlandes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.